Log In
Print this Print this

RTH258 (formerly ESBA1008)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionNext-generation single-chain anti-VEGF antibody fragment
Molecular Target Vascular endothelial growth factor (VEGF)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat wet age-related macular degeneration (AMD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today